SCHEMBL6095614

SCHEMBL6095614

O=C(O)C1(S(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)CCN(c2nccc(C(F)(F)F)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.47
SCN9A Q15858 2/20 0.43
KCNH2 Q12809 1/20 0.43
SCN5A Q14524 1/20 0.43
MMP13 P45452 6/20 0.42
MMP2 P08253 5/20 0.42
FPR2 P25090 1/20 0.41
PROKR1 Q8TCW9 1/20 0.41
MMP12 P39900 1/20 0.40
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC6A7 Q99884 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094513 0.91 MMP2 (0.48) ACACBSCN9AKCNH2SCN5AMMP13
SCHEMBL6095298 0.91 ACACB (0.49) ACACBSCN9AKCNH2SCN5AMMP13
SCHEMBL6095160 0.90 MMP13 (0.47) SCN9AKCNH2SCN5AMMP13MMP2
SCHEMBL6098511 0.84 ACACB (0.42) ACACBSCN9AKCNH2SCN5AMMP13
SCHEMBL6098501 0.82 GPR119 (0.44) ACACBSCN9AKCNH2SCN5AMMP13
SCHEMBL6097326 0.81 MMP13 (0.51) SCN9AKCNH2SCN5AMMP13MMP2
SCHEMBL6097350 0.81 MMP13 (0.47) ACACBSCN9AKCNH2SCN5AMMP13
SCHEMBL6097841 0.79 MMP13 (0.49) MMP13MMP2FPR2PROKR1MMP12
SCHEMBL6099731 0.79 MMP13 (0.49) MMP13MMP2FPR2PROKR1MMP12
SCHEMBL6096620 0.76 ADRB2 (0.52) KCNH2MMP13MMP2MMP12LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 ACACB 1900/4885SCN9A 2518/4885KCNH2 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.